Hikma Adds Another Celltrion Biosimilar To MENA Collaboration
Also Launches Pre-Filled Syringe Version Of Naloxone 2mg/2ml In US
Hikma has further expanded its portfolio of biosimilars in the MENA region with the addition of Celltrion’s Vegzelma bevacizumab rival to Avastin. Meanwhile, Hikma has also just launched a new pre-filled syringe version of naloxone in the US.
You may also be interested in...
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
Hikma has debuted a pre-filled syringe formulation of succinylcholine chloride in the US, representing the first FDA-approved PFS version of the product to be launched in the market.
Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.